These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Hypofractionated versus conventionally fractionated image-guided volumetric-modulated arc radiotherapy for localized prostate cancer: a phase II randomized trial from China. Zhong QZ; Xia X; Gao H; Xu YG; Zhao T; Wu QH; Wang D; Lin HL; Sha XY; Liu M; Li GF Aging (Albany NY); 2021 Feb; 13(5):6936-6944. PubMed ID: 33653964 [TBL] [Abstract][Full Text] [Related]
8. Moderate hypofractionated radiotherapy for post-operative treatment of prostate cancer: long-term outcome and pattern of toxicity. Franzese C; Badalamenti M; Baldaccini D; D'Agostino G; Comito T; Franceschini D; Clerici E; Navarria P; Reggiori G; Tomatis S; Scorsetti M Strahlenther Onkol; 2021 Feb; 197(2):133-140. PubMed ID: 33006025 [TBL] [Abstract][Full Text] [Related]
9. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study. Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594 [TBL] [Abstract][Full Text] [Related]
10. Moderate hypofractionated post-prostatectomy radiation therapy is feasible and well tolerated: experience from a single tertiary cancer centre. Valero J; Montero A; Hernando O; Izquierdo M; Sánchez E; García-Aranda M; López M; Ciérvide R; Martí J; Álvarez B; Alonso R; Chen-Zhao X; Fernández-Letón P; Rubio C Clin Transl Oncol; 2021 Jul; 23(7):1452-1462. PubMed ID: 33433839 [TBL] [Abstract][Full Text] [Related]
11. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N; Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791 [TBL] [Abstract][Full Text] [Related]
12. Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study. Jorgo K; Polgar C; Major T; Stelczer G; Herein A; Pocza T; Gesztesi L; Agoston P Pathol Oncol Res; 2020 Apr; 26(2):905-912. PubMed ID: 30888646 [TBL] [Abstract][Full Text] [Related]
13. Transitioning from conformal radiotherapy to intensity-modulated radiotherapy after radical prostatectomy: Clinical benefit, oncologic outcomes and incidence of gastrointestinal and urinary toxicities. Flores-Balcázar CH; Urías-Arce DM; Bourlon MT; Gabilondo-Navarro F; Pérez-Álvarez SI; Ramos-Prudencio R; Rodríguez-Covarrubias F Rep Pract Oncol Radiother; 2020; 25(4):568-573. PubMed ID: 32494230 [TBL] [Abstract][Full Text] [Related]
14. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964 [TBL] [Abstract][Full Text] [Related]
15. Hypofractionated radiotherapy for prostate cancer in the postoperative setting: What is the evidence so far? Picardi C; Perret I; Miralbell R; Zilli T Cancer Treat Rev; 2018 Jan; 62():91-96. PubMed ID: 29178983 [TBL] [Abstract][Full Text] [Related]
16. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373 [TBL] [Abstract][Full Text] [Related]
17. Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy. Beck M; Wust P; Barelkowski T; Kaul D; Thieme AH; Wecker S; Wlodarczyk W; Budach V; Ghadjar P Radiat Oncol; 2017 Aug; 12(1):125. PubMed ID: 28793907 [TBL] [Abstract][Full Text] [Related]
18. Hypofractionation with VMAT versus 3DCRT in post-operative patients with prostate cancer. Alongi F; Cozzi L; Fogliata A; Iftode C; Comito T; Clivio A; Villa E; Lobefalo F; Navarria P; Reggiori G; Mancosu P; Clerici E; Tomatis S; Taverna G; Graziotti P; Scorsetti M Anticancer Res; 2013 Oct; 33(10):4537-43. PubMed ID: 24123027 [TBL] [Abstract][Full Text] [Related]
19. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer. Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889 [TBL] [Abstract][Full Text] [Related]
20. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy. Wong GW; Palazzi-Churas KL; Jarrard DF; Paolone DR; Graf AK; Hedican SP; Wegenke JD; Ritter MA Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):449-55. PubMed ID: 17869014 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]